Warsaw University Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2011
NCT01493089
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Children's Hospital, Dziekanów Leśny, Poland | Dept of Gastroenterology and Hepatology, Roentgena, Warsaw, Poland | Institute of Psychiatry and Neurology, Warsaw | Institute of Psychiatry and Neurology, Warsaw, Poland | Roentgena, Warsaw, Poland | University of Warsaw

Active Ingredients

Drugs in Phase 3 Trials (4)

cladribine (leustatin) (1 trial)

omeprazole (prilosec) (1 trial)

sodium bicarbonate (1 trial)

sodium chloride (1 trial)

Drugs in Other Trials (1)

lactobacillus reuteri (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Esophagitis, Peptic (Phase 3)

Gastroesophageal Reflux (Phase 3)

Heartburn (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5